Search results
FDA panel rejects MDMA-based treatment for PTSD
The Hill via Yahoo News· 1 hour agoA potential treatment for post-traumatic stress disorder using the psychedelic MDMA was overwhelmingly rejected by a panel of federal regulators on...
FDA Panel Rejects MDMA Therapy For PTSD, Citing Concerns Over Research Data In Setback For Advocates
Benzinga· 1 hour agoA committee of advisors to the U.S. Food and Drug Administration (FDA) dealt a blow to the...
FDA panel rejects psychedelic drug MDMA as a PTSD treatment - The Boston Globe
The Boston Globe· 3 hours agoThe FDA is not required to follow the group’s advice and is expected to make its final decision by...
Dessert recall sparks warning in two states
Newsweek· 1 hour agoA strawberry rhubarb tart has been recalled on Tuesday, impacting stores in Oregon and Washington. According to an allergy alert posted by the U.S. Food...
FDA Panel to Consider Updating COVID-19 Jabs for New Virus Strains
Zacks via Yahoo Finance· 12 hours agoAn FDA panel meeting is scheduled on Jun 5 to consider if COVID-19 vaccines should be updated to...
FDA advisers vote against recommending approval of MDMA as treatment for PTSD
ABC News· 6 hours agoA panel of independent advisers for the U.S. Food and Drug Administration voted against recommending...
FDA advisers vote against first MDMA therapy to treat PTSD
CNN via Yahoo News· 5 hours agoA federal advisory committee on Tuesday voted overwhelmingly against of the use of MDMA, commonly...
FDA advisory panel votes against allowing MDMA as PTSD treatment
United Press International via Yahoo News· 3 hours agoThe popular underground drug midomafetamine, also called MDMA and "ecstasy," failed to win an...
FDA panel rejects first MDMA treatment amid deep concerns about flawed trials
NBC News via Yahoo News· 3 hours agoA Food and Drug Administration advisory panel on Tuesday declined to recommend the approval of MDMA,...
Flawed, scandalous trials tank FDA expert support for MDMA therapy
Ars Technica· 5 hours agoIn response to the second question, "Do the benefits of midomafetamine with FDA’s proposed risk...